查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2008910

卵巢癌市场报告：按类型、治疗方法、最终用户和地区划分（2026-2034 年）

Ovarian Cancer Market Report by Type, Treatment Type, End User, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 135 Pages | 商品交期: 2-3个工作天内

价格

2025年，全球卵巢癌市场规模达25亿美元。展望未来，IMARC集团预测，到2034年，该市场规模将达到58亿美元，2026年至2034年的复合年增长率（CAGR）为9.21%。北美地区凭藉其先进的医疗基础设施、强大的科研能力以及对创新治疗方法的旺盛需求，正引领市场成长。卵巢癌发生率的上升、癌症治疗中个人化医疗的兴起以及政府主导的旨在提高公众意识、促进早期检测和支持研究的各项倡议，都是推动市场成长的关键因素。

卵巢癌是一种发生在卵巢的癌症，卵巢是女性的生殖器官，负责产生卵子和雌激素。卵巢癌通常是由于卵巢内的异常细胞不受控制地增殖并形成肿瘤而引起的。卵巢癌有多种类型，根据其起源细胞的不同进行分类。最常见的类型是上皮性卵巢癌，它起源于卵巢表面。其他相对罕见的类型包括生殖细胞肿瘤和间质肿瘤，它们分别起源于产生卵子和荷尔蒙的细胞。卵巢癌的常见症状包括腹胀、骨盆和腹部疼痛、食慾不振或容易饱腹、频尿以及排便习惯改变。

标靶治疗、免疫疗法和个人化医疗的进步正在拓展治疗选择。这些治疗方法比传统化疗更有效、副作用更少，从而改善了患者的预后。此外，临床试验的进展正在推动创新，促使新治疗方法的研发，为提高患者的存活率和生活品质带来了希望。同时，製药公司、研究机构和非营利组织之间的合作也在推动卵巢癌治疗的进步。这种合作汇集了资源和专业知识，以改善药物研发、临床试验和宣传活动。团队合作能够迅速将研究成果转化为有效的治疗方法，并改善卵巢癌治疗的整体市场前景。此外，人们对卵巢癌的认识不断提高，从而实现了早期诊断，这对于提高存活率至关重要。健康宣传宣传活动和倡议团体正在向人们普及症状和风险因素，鼓励更多女性就医。早期筛检技术的改进提高了现有治疗方法的有效性。

卵巢癌市场趋势：

扩大医疗保健投资和政府主导的倡议

世界各国政府日益认识到癌症影响的不断扩大，并增加对癌症研究、治疗倡议和创新医疗技术发展的投入。这些投资正在加速卵巢癌新疗法、诊断设备和先进调查方法的研发。此外，製药公司、生技公司和学术机构之间的伙伴关係正在加速新治疗方法的发现。这些合作正在创造更具针对性、个人化和高效的治疗方案。同时，资金支持的增加正在加速临床试验的发展和创新治疗方法的快速实用化。这些合作努力将改善患者照护，提高存活率，并为持续研究提供更多资源，最终促进卵巢癌市场的成长并改善患者的治疗效果。

标靶治疗和新治疗标准的核准

标靶治疗的引入以及针对特定卵巢癌亚型的新治疗标准的建立正在推动市场成长。我们对卵巢癌遗传和分子基础的认识不断加深，促使人们开发出针对特定突变的治疗方法，为患者提供更有效的治疗选择。在临床试验中展现出良好疗效并获得监管部门核准的新治疗方法，正在提供更个人化和精准的治疗，从而改善患者的预后。标靶治疗的这些进展提高了存活率，同时也增加了对专业治疗的需求，进一步推动了卵巢癌产业的成长和投资。 2025年5月，美国食品药物管理局（FDA）核准了Verastem Oncology公司用于治疗KRAS突变型低度浆液性卵巢（LGSOC）的联合治疗，使其成为首个获准用于治疗这种罕见癌症的治疗方法。在II期临床试验中，abutometinib和defactinib的联合治疗显示出44%的客观缓解率。此次核准确立了该疗法作为KRAS突变型复发性LGSOC新标准治疗方案的地位。

研究进展和治疗方案

创新治疗方法的不断进步显着推动了卵巢癌市场的成长，提高了治疗效果和患者预后。标靶治疗、免疫疗法和个人化医疗的进步为患者提供了更个人化和有效的治疗选择。这些进步提高了存活率和治疗效果，从而促进了市场成长。此外，生物标记和基因谱分析的研究使得更有针对性和更及时的治疗成为可能，进而加速了卵巢癌治疗的市场参与和资金筹措。 2025年，Tilt Biotherapeutics公司在B轮资金筹措中筹集了2,260万欧元（2,560万美元），用于推进其肿瘤病毒疗法「TILT-123」进入含铂类药物抗药性卵巢癌（PROC）的II期临床试验。此治疗方法与默克公司的「Keytruda」等T细胞治疗方法合併使用，初步结果令人鼓舞，64%的病患病情得到控制。

卵巢癌市场成长要素：

扩大综合癌症筛检计划

全面癌症筛检倡议的推广是卵巢癌市场的主要驱动力。这些计划着重于癌症的早期发现，从而提高治疗成功率并改善患者预后。透过整合性别特异性诊断、遗传性癌症风险评估和肿瘤标记检测，这些计划提供了一种全面的癌症检测策略。随着人们对早期发现重要性的认识不断提高，对便利且经济实惠的筛检方案的需求日益增长，尤其是在癌症发病率不断上升的地区。扩大筛检服务的覆盖范围不仅有助于早期疗育，还能扩大诊断工具的市场，并推动卵巢癌领域创新产品和服务的需求。 2025年，Metropolis Healthcare推出了TruHealth Cancer Screen 360，这是一个旨在提高印度早期癌症检测率的全面癌症筛检方案。此方案包含性别特异性诊断、遗传性癌症风险分析以及多种癌症的肿瘤标记检测。该计划旨在透过提高筛检的可近性和可负担性，来应对日益严重的癌症负担，尤其是在都市区和都市区。

基因检测和风险评估计划的兴起

日益重视识别具有遗传易感性的个体，有助于更早发现疾病并采取个人化的预防措施。这种向预防性医疗保健的转变，使得有针对性的干预成为可能，从而改善治疗效果，并最终降低发病率。随着基因检测的普及，尤其是在高风险族群及其家庭中，对相关诊断服务、治疗和教育资源的需求也日益增长。此外，这些努力将帮助患者做出明智的健康选择，最终透过提高公众意识和扩大早期检测工具的获取途径，促进市场成长。 2024年，史丹佛大学医学院收到Bright Pink的350万美元遗赠，用于推出Bright Pink预防风险推广和级联检测（PROACT）计画。该计画专注于高风险族群及其家庭，旨在推广乳癌和卵巢癌的基因检测。该计画建立在Bright Pink以往工作的基础上，旨在改善基因风险评估的可近性，并支持积极主动的健康管理。

人工智慧驱动的癌症研究进展

人工智慧 (AI) 在卵巢癌研究中的应用，透过提升早期检测能力、优化个人化治疗策略并加速研究进展，正在推动市场成长。 AI 技术能够分析大规模资料集，揭示以往难以发现的模式和洞见。透过利用机器学习 (ML) 演算法处理患者数据，研究人员可以开发更精准的诊断工具、改进治疗通讯协定并预测患者预后。随着 AI 不断革新调查方法，治疗效果和存活率的提高将增加对创新癌症治疗方案的需求，从而进一步推动市场成长。 2025 年，全球卵巢癌研究联盟与微软「AI for Good Lab」合作，推出了一项 100 万美元的「AI 加速器津贴」。该计划旨在利用 AI 技术提高卵巢癌存活率并推进相关研究。该津贴将用于支持跨国跨领域研究团队，共同应对全球卵巢癌危机。

目录

第一章：序言

第二章：调查方法

  • 调查目的
  • 相关利益者
  • 数据来源
    • 主要讯息
    • 次要讯息
  • 市场估值
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章执行摘要

第四章：引言

第五章：全球卵巢癌市场

  • 市场概览
  • 市场表现
  • 新冠疫情的影响
  • 市场预测

第六章 市场区隔：依类型

  • 上皮性卵巢癌
  • 生殖细胞卵巢卵巢
  • 卵巢间质细胞卵巢

第七章 市场区隔：依治疗类型划分

  • 免疫疗法
  • 化疗
  • 标靶治疗
  • 外科手术
  • 其他的

第八章 市场区隔：依最终用户划分

  • 医院
  • 居家照护
  • 专业医疗中心
  • 其他的

第九章 市场区隔：依地区划分

  • 北美洲
    • 我们
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第十章 SWOT 分析

第十一章：价值链分析

第十二章：波特五力分析

第十三章：价格分析

第十四章 竞争格局

  • 市场结构
  • 主要企业
  • 主要企业简介
    • AbbVie Inc.
    • Amneal Pharmaceuticals Inc.
    • AstraZeneca plc
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG
    • GSK plc
    • Hikma Pharmaceuticals PLC
    • Lupin Limited
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd.
Product Code: SR112026A6407

The global ovarian cancer market size reached USD 2.5 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 5.8 Billion by 2034, exhibiting a growth rate (CAGR) of 9.21% during 2026-2034. North America leads the market attributed to its advanced healthcare infrastructure, strong research capabilities, and high demand for innovative treatment options. The rising incidence of ovarian cancer cases, the emergence of personalized medicine in cancer care, and the implementation of government Initiatives to raise awareness, promote early detection, and support research represent some of the key factors driving the market.

Ovarian cancer is a type of cancer that begins in the ovaries, the female reproductive organs responsible for producing eggs and female hormones. It typically develops when abnormal cells in the ovaries grow and multiply uncontrollably, forming a tumor. There are different types of ovarian cancer, and they can be classified based on the specific cells from which they originate. The most common type is epithelial ovarian cancer, which arises from the surface of the ovary. Other less common types include germ cell tumors and stromal tumors, which develop from the cells that produce eggs and hormones, respectively. Common symptoms of ovarian cancer include abdominal bloating, pelvic or abdominal pain, difficulty eating or feeling full quickly, frequent urination, and changes in bowel habits.

The development of targeted treatments, immune therapies, and individualized medicine is broadening therapeutic choices. These therapies are more efficient and less harmful than conventional chemotherapy, enhancing patient results. Moreover, advancements in clinical trials are fostering innovation, encouraging new treatments that provide optimism for improved survival rates and enhanced quality of life for patients. Besides this, collaborative partnerships among pharmaceutical firms, research organizations, and non-profit entities are driving advancements in ovarian cancer therapies. These collaborations improve drug development, clinical trials, and awareness initiatives by combining resources and expertise. Teamwork accelerates the translation of research into effective treatments and enhances the overall market outlook for ovarian cancer treatment. Furthermore, the growing awareness about ovarian cancer is leading to earlier diagnosis, which is essential for enhancing survival rates. Health campaigns and advocacy organizations are informing individuals about symptoms and risk elements, encouraging more women to pursue medical consultation. Timely detection via enhanced screening methods boosts the efficacy of current therapies.

OVARIAN CANCER MARKET TRENDS:

Increased Healthcare Investments and Government Initiatives

Governments around the globe, are becoming more aware about the increasing impact of cancer, are directing additional resources towards research, treatment initiatives, and the advancement of innovative medical technologies. These investments facilitate the discovery of novel therapeutic strategies, improved diagnostic instruments, and refined treatment methodologies for ovarian cancer. In addition, partnerships among pharmaceutical companies, biotech organizations, and academic institutions are speeding up the identification of new treatments. These collaborations result in the creation of more focused, individualized, and efficient treatment alternatives. Apart from this, the heightened financial backing promotes the growth of clinical trials and the swift commercialization of innovative therapies. This collaborative endeavor boosts patient care, increases survival rates, and guarantees that additional resources are accessible for ongoing research, ultimately contributing to the growth of the ovarian cancer market and enhancing patient outcomes.

Approval of Targeted Therapies and New Treatment Standards

The introduction of targeted therapies and the creation of new treatment benchmarks for particular ovarian cancer subtypes are bolstering the market growth. Progress in comprehending the genetic and molecular foundations of ovarian cancer is resulting in the creation of therapies that focus on particular mutations, providing patients with more effective treatment choices. With new therapies showing encouraging effectiveness in clinical trials and receiving regulatory approval, they offer more tailored and accurate care, enhancing patient outcomes. This advancement in targeted therapies is increasing survival rates while also generating higher demand for specialized treatments, driving further growth and investment in the ovarian cancer industry. In May 2025, the FDA approved Verastem Oncology's drug combination for low-grade serous ovarian cancer (LGSOC) driven by KRAS mutations, marking the first treatment for this rare cancer. The combination of avutometinib and defactinib showed a 44% response rate in a Phase 2 study. This approval sets the therapy as the new standard of care for recurrent LGSOC with KRAS mutations.

Advancements in Research and Treatment Options

The continuous advancement of innovative therapies is significantly driving the growth of the ovarian cancer market by improving treatment efficacy and patient outcomes. Advances in targeted treatments, immunotherapy, and personalized medicine offer patients more customized and effective options for therapy. These developments enhance survival rates and treatment effectiveness, contributing to the market growth. Besides this, studies on biomarkers and genetic profiling are resulting in more targeted and timely treatments, which consequently enhances market engagement and funding in ovarian cancer therapies. In 2025, Tilt Biotherapeutics raised €22.6 million ($25.6 million) in Series B funding to advance its oncolytic virus therapy, TILT-123, into a Phase II trial for platinum-resistant ovarian cancer (PROC). The therapy, combined with T cell-based treatments like Merck's Keytruda, showed promising early results, with 64% of patients achieving disease control.

OVARIAN CANCER MARKET GROWTH DRIVERS:

Expansion of Comprehensive Cancer Screening Programs

The expansion of thorough cancer screening initiatives is a major factor influencing the ovarian cancer market. These initiatives focus on identifying cancer during its initial phases, allowing for more successful therapies and better patient results. Through the integration of gender-specific diagnostics, hereditary cancer risk assessment, and tumor markers, these initiatives offer a thorough strategy for cancer detection. As knowledge about the significance of early detection expands, the need for accessible and cost-effective screening options rises, especially in areas with increasing cancer rates. This broader access to screening services not only facilitates earlier intervention but also expands the market for diagnostic tools, driving the demand for innovative products and services in the ovarian cancer space. In 2025, Metropolis Healthcare launched the TruHealth Cancer Screen 360, a comprehensive cancer screening panel aimed at improving early cancer detection in India. The panel includes gender-specific diagnostics, hereditary cancer risk analysis, and tumor markers for multiple cancers. This initiative seeks to address the rising cancer burden, especially in urban and non-urban areas, by making screening more accessible and affordable.

Rise of Genetic Testing and Risk Assessment Initiatives

Enhanced emphasis on identifying individuals with greater genetic susceptibility allows for earlier identification and tailored prevention approaches. This transition towards proactive healthcare enables focused interventions, resulting in better outcomes and possibly lower incidence rates. With genetic testing becoming increasingly available, especially for at-risk individuals and their families, the need for associated diagnostic services, treatments, and educational resources grows. Moreover, these efforts enable patients to make knowledgeable choices regarding their health, ultimately supporting the market growth through heightened awareness and access to early detection tools. In 2024, Stanford Medicine received a $3.5 million legacy gift from Bright Pink to launch the Bright Pink Preventive Risk Outreach and Cascade Testing (PROACT) Program. The initiative aimed to increase genetic testing for breast and ovarian cancer, focusing on at-risk individuals and their families. The program builds on Bright Pink's previous work, making genetic risk assessments more accessible and empowering proactive health management.

Advancements in AI-Driven Cancer Research

The incorporation of artificial intelligence (AI) into ovarian cancer studies is propelling market growth by enhancing early detection, personalized treatment strategies, and accelerating research advancements. AI technologies allow for the examination of large datasets, revealing patterns and insights that were once challenging to discover. Utilizing machine learning (ML) algorithms on patient data enables researchers to create more precise diagnostic tools, enhance treatment protocols, and anticipate patient outcomes. As AI continues to transform research methodologies, it enhances the effectiveness of treatments and improves survival rates, thereby increasing the demand for innovative cancer care solutions and further supporting the market growth. In 2025, the Global Ovarian Cancer Research Consortium launched a $1 million AI Accelerator Grant in partnership with Microsoft's AI for Good Lab. The initiative aims to advance ovarian cancer research by using AI to improve survival rates. The grant will fund multi-country, multidisciplinary research teams to tackle the global ovarian cancer crisis.

OVARIAN CANCER INDUSTRY SEGMENTATION:

Breakup by Type:

  • Epithelial Ovarian Cancer
  • Germ Cell Ovarian Cancer
  • Stromal Cell Ovarian Cancer

Epithelial ovarian cancer represents the leading type

Epithelial ovarian cancer is more commonly diagnosed in older women, and as the global population ages, the incidence of ovarian cancer tends to increase. The risk of developing ovarian cancer rises significantly after menopause, making postmenopausal women more susceptible to this type of cancer. Moreover, obesity and unhealthy lifestyle choices, such as poor diet and lack of physical activity, have been associated with an increased risk of ovarian cancer. The global rise in obesity rates over the past few decades may have contributed to the growing prevalence of epithelial ovarian cancer. Besides, certain genetic mutations, such as BRCA1 and BRCA2 mutations, are known to increase the risk of developing ovarian cancer. Inherited genetic factors can play a significant role in the prevalence of epithelial ovarian cancer, especially in families with a history of the disease.

Breakup by Treatment Type:

  • Immunotherapy
  • Chemotherapy
  • Targeted Therapy
  • Surgery
  • Others

Immunotherapy is the most popular treatment type

Immunotherapy has emerged as a revolutionary approach in cancer treatment, showing promising results in various cancer types. Ovarian cancer, being one of the deadliest gynecological malignancies, has been a focus of research to identify novel and more effective therapies. Immunotherapy's success in other cancer types has generated significant interest in exploring its potential benefits in ovarian cancer treatment. Moreover, immunotherapy focuses on targeting the tumor microenvironment, which includes various immune cells and signaling molecules that support tumor growth and progression. By modulating the immune response, immunotherapy aims to create an inhospitable environment for cancer cells, hindering their growth and spread.

Breakup by End User:

  • Hospitals
  • Homecare
  • Speciality Centre
  • Others

Hospitals are the primary healthcare institutions that play a crucial role in the diagnosis, treatment, and management of ovarian cancer. They offer a comprehensive range of medical services, including surgery, chemotherapy, radiation therapy, and supportive care for ovarian cancer patients. Hospitals typically have specialized oncology departments or cancer centers equipped with advanced medical technology and a multidisciplinary team of healthcare professionals, including oncologists, surgeons, nurses, and support staff.

Homecare services may include nursing care, administration of medications, pain management, wound care, and assistance with activities of daily living. Homecare is particularly beneficial for patients who require ongoing support and monitoring but prefer to receive treatment in a familiar environment. Homecare services aim to enhance the quality of life for ovarian cancer patients, allowing them to remain in their homes while receiving necessary medical attention.

Specialty centers are dedicated healthcare facilities that focus on specific medical conditions or diseases, including ovarian cancer. These centers offer specialized expertise, state-of-the-art facilities, and advanced treatment options tailored to the needs of ovarian cancer patients. Specialty centers include oncology clinics, cancer institutes, and women's health centers that provide comprehensive care, support, and access to cutting-edge therapies and clinical trials for ovarian cancer.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America accounts for the majority of market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (United States, Canada); Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others); Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others); Latin America (Brazil, Mexico, Others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America boasts a well-established and technologically advanced healthcare infrastructure, with a high concentration of hospitals, specialty centers, and cancer institutes equipped with state-of-the-art medical facilities and cutting-edge technologies. This enables efficient diagnosis, treatment, and follow-up care for ovarian cancer patients. Moreover, the region is a hub for biomedical research and development, with numerous pharmaceutical and biotechnology companies conducting extensive research on cancer therapies, including ovarian cancer. Ongoing research and clinical trials contribute to the development of innovative treatment options and novel drugs, making North America a frontrunner in ovarian cancer treatment advancements.

COMPETITIVE LANDSCAPE:

The competitive landscape of the ovarian cancer market is characterized by a mix of pharmaceutical companies, biotechnology firms, and academic institutions actively engaged in research, development, and commercialization of treatments and therapies. These companies are developing and commercializing chemotherapy drugs, targeted therapies, and immunotherapies for ovarian cancer treatment. They are also focusing on novel drug development and personalized treatment options. Moreover, various companies are identifying new drug targets, exploring combination therapies, and conducting clinical trials to assess the safety and efficacy of their investigational drugs. They are also forming strategic partnerships with academic institutions, research organizations, and other biopharmaceutical firms to access complementary expertise, resources, and technologies.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • AbbVie Inc.
  • Amneal Pharmaceuticals Inc.
  • AstraZeneca plc
  • Eli Lilly and Company
  • F. Hoffmann-La
  • Roche AG
  • GSK plc
  • Hikma Pharmaceuticals PLC
  • Lupin Limited
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the ovarian cancer market?

2. What is the future outlook of the ovarian cancer market?

3. What are the key factors driving the ovarian cancer market?

4. Which region accounts for the largest ovarian cancer market share?

5. Which are the leading companies in the global ovarian cancer market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Ovarian Cancer Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Epithelial Ovarian Cancer
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Germ Cell Ovarian Cancer
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Stromal Cell Ovarian Cancer
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Treatment Type

  • 7.1 Immunotherapy
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Chemotherapy
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Targeted Therapy
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Surgery
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Homecare
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Speciality Centre
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 AbbVie Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Amneal Pharmaceuticals Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
    • 14.3.3 AstraZeneca plc
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Eli Lilly and Company
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 F. Hoffmann-La Roche AG
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
    • 14.3.6 GSK plc
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Hikma Pharmaceuticals PLC
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Lupin Limited
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Pfizer Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Teva Pharmaceutical Industries Ltd.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Ovarian Cancer Market: Major Drivers and Challenges
  • Figure 2: Global: Ovarian Cancer Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Ovarian Cancer Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Ovarian Cancer Market: Breakup by Type (in %), 2025
  • Figure 5: Global: Ovarian Cancer Market: Breakup by Treatment Type (in %), 2025
  • Figure 6: Global: Ovarian Cancer Market: Breakup by End User (in %), 2025
  • Figure 7: Global: Ovarian Cancer Market: Breakup by Region (in %), 2025
  • Figure 8: Global: Ovarian Cancer (Epithelial Ovarian Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 9: Global: Ovarian Cancer (Epithelial Ovarian Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 10: Global: Ovarian Cancer (Germ Cell Ovarian Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Ovarian Cancer (Germ Cell Ovarian Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Ovarian Cancer (Stromal Cell Ovarian Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Ovarian Cancer (Stromal Cell Ovarian Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Ovarian Cancer (Immunotherapy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Ovarian Cancer (Immunotherapy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Ovarian Cancer (Chemotherapy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Ovarian Cancer (Chemotherapy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Ovarian Cancer (Targeted Therapy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Ovarian Cancer (Targeted Therapy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Ovarian Cancer (Surgery) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Ovarian Cancer (Surgery) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Ovarian Cancer (Other Treatment Types) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Ovarian Cancer (Other Treatment Types) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Ovarian Cancer (Hospitals) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Ovarian Cancer (Hospitals) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Ovarian Cancer (Homecare) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Ovarian Cancer (Homecare) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: Ovarian Cancer (Speciality Centre) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: Ovarian Cancer (Speciality Centre) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: Global: Ovarian Cancer (Other End Users) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: Global: Ovarian Cancer (Other End Users) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: North America: Ovarian Cancer Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: North America: Ovarian Cancer Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: United States: Ovarian Cancer Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: United States: Ovarian Cancer Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: Canada: Ovarian Cancer Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: Canada: Ovarian Cancer Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Asia-Pacific: Ovarian Cancer Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Asia-Pacific: Ovarian Cancer Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: China: Ovarian Cancer Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: China: Ovarian Cancer Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: Japan: Ovarian Cancer Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: Japan: Ovarian Cancer Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: India: Ovarian Cancer Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: India: Ovarian Cancer Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: South Korea: Ovarian Cancer Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: South Korea: Ovarian Cancer Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: Australia: Ovarian Cancer Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: Australia: Ovarian Cancer Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: Indonesia: Ovarian Cancer Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: Indonesia: Ovarian Cancer Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: Others: Ovarian Cancer Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: Others: Ovarian Cancer Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: Europe: Ovarian Cancer Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: Europe: Ovarian Cancer Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: Germany: Ovarian Cancer Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: Germany: Ovarian Cancer Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: France: Ovarian Cancer Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: France: Ovarian Cancer Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: United Kingdom: Ovarian Cancer Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: United Kingdom: Ovarian Cancer Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: Italy: Ovarian Cancer Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: Italy: Ovarian Cancer Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Spain: Ovarian Cancer Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Spain: Ovarian Cancer Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Russia: Ovarian Cancer Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Russia: Ovarian Cancer Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Others: Ovarian Cancer Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: Others: Ovarian Cancer Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Latin America: Ovarian Cancer Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Latin America: Ovarian Cancer Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Brazil: Ovarian Cancer Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Brazil: Ovarian Cancer Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Mexico: Ovarian Cancer Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Mexico: Ovarian Cancer Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: Others: Ovarian Cancer Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 77: Others: Ovarian Cancer Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 78: Middle East and Africa: Ovarian Cancer Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 79: Middle East and Africa: Ovarian Cancer Market: Breakup by Country (in %), 2025
  • Figure 80: Middle East and Africa: Ovarian Cancer Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 81: Global: Ovarian Cancer Industry: SWOT Analysis
  • Figure 82: Global: Ovarian Cancer Industry: Value Chain Analysis
  • Figure 83: Global: Ovarian Cancer Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Ovarian Cancer Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Ovarian Cancer Market Forecast: Breakup by Type (in Million USD), 2026-2034
  • Table 3: Global: Ovarian Cancer Market Forecast: Breakup by Treatment Type (in Million USD), 2026-2034
  • Table 4: Global: Ovarian Cancer Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 5: Global: Ovarian Cancer Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Ovarian Cancer Market: Competitive Structure
  • Table 7: Global: Ovarian Cancer Market: Key Players